JP2020535811A - 特異的結合分子 - Google Patents

特異的結合分子 Download PDF

Info

Publication number
JP2020535811A
JP2020535811A JP2020517953A JP2020517953A JP2020535811A JP 2020535811 A JP2020535811 A JP 2020535811A JP 2020517953 A JP2020517953 A JP 2020517953A JP 2020517953 A JP2020517953 A JP 2020517953A JP 2020535811 A JP2020535811 A JP 2020535811A
Authority
JP
Japan
Prior art keywords
vnar
binding molecule
domain
specific binding
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517953A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535811A5 (https=
Inventor
ウバー，オビナ
バレル，キャロライン
ポーター，アンドリュー
Original Assignee
エラスモーゲン リミテッド
エラスモーゲン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラスモーゲン リミテッド, エラスモーゲン リミテッド filed Critical エラスモーゲン リミテッド
Publication of JP2020535811A publication Critical patent/JP2020535811A/ja
Publication of JP2020535811A5 publication Critical patent/JP2020535811A5/ja
Priority to JP2023149770A priority Critical patent/JP7818828B2/ja
Priority to JP2025127980A priority patent/JP2025160405A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020517953A 2017-09-27 2018-09-27 特異的結合分子 Pending JP2020535811A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023149770A JP7818828B2 (ja) 2017-09-27 2023-09-15 特異的結合分子
JP2025127980A JP2025160405A (ja) 2017-09-27 2025-07-31 特異的結合分子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762563948P 2017-09-27 2017-09-27
US62/563,948 2017-09-27
US201862667126P 2018-05-04 2018-05-04
US62/667,126 2018-05-04
PCT/EP2018/076333 WO2019063726A1 (en) 2017-09-27 2018-09-27 SPECIFIC BINDING MOLECULES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149770A Division JP7818828B2 (ja) 2017-09-27 2023-09-15 特異的結合分子

Publications (2)

Publication Number Publication Date
JP2020535811A true JP2020535811A (ja) 2020-12-10
JP2020535811A5 JP2020535811A5 (https=) 2021-11-04

Family

ID=63720686

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517953A Pending JP2020535811A (ja) 2017-09-27 2018-09-27 特異的結合分子
JP2023149770A Active JP7818828B2 (ja) 2017-09-27 2023-09-15 特異的結合分子
JP2025127980A Pending JP2025160405A (ja) 2017-09-27 2025-07-31 特異的結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023149770A Active JP7818828B2 (ja) 2017-09-27 2023-09-15 特異的結合分子
JP2025127980A Pending JP2025160405A (ja) 2017-09-27 2025-07-31 特異的結合分子

Country Status (7)

Country Link
US (2) US11919949B2 (https=)
EP (2) EP3688030B1 (https=)
JP (3) JP2020535811A (https=)
KR (1) KR102657978B1 (https=)
CN (1) CN111479825A (https=)
CA (1) CA3075367A1 (https=)
WO (1) WO2019063726A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190233832A1 (en) * 2016-07-19 2019-08-01 National Agriculture And Food Research Organization Method for introducing substance into plant cell using plasma
WO2021028837A1 (en) * 2019-08-13 2021-02-18 Waters Technologies Corporation Affinity resins and sample preparation devices based on cartilaginous fish ignar derived binding domains
GB202020152D0 (en) * 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
CN118475603A (zh) * 2021-11-03 2024-08-09 香港城市大学深圳研究院 高亲和力抗EGFP和抗SARS-CoV-2 vNAR单域抗体及其用途
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200883A2 (en) * 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
JP2016524592A (ja) * 2013-04-23 2016-08-18 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
PE20141522A1 (es) * 2011-08-17 2014-11-17 Glaxo Group Ltd Proteinas y peptidos modificados
EP4151658A1 (en) 2012-05-07 2023-03-22 Elasmogen Limited Single domain binding molecule

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016524592A (ja) * 2013-04-23 2016-08-18 ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
WO2015200883A2 (en) * 2014-06-26 2015-12-30 Ossianix, Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN. BIOL. THER., vol. 14, no. 10, JPN6022038396, 2014, pages 1527 - 1539, ISSN: 0005058474 *
MABS, vol. 5, no. 1, JPN6022038397, 2013, pages 80 - 85, ISSN: 0005058475 *
SCIENTIFIC REPORTS, vol. Vol. 7:9676, JPN6022038395, 29 August 2017 (2017-08-29), pages 1 - 13, ISSN: 0005058473 *

Also Published As

Publication number Publication date
JP2025160405A (ja) 2025-10-22
JP7818828B2 (ja) 2026-02-24
US20240247058A1 (en) 2024-07-25
JP2023175822A (ja) 2023-12-12
US11919949B2 (en) 2024-03-05
EP3688030A1 (en) 2020-08-05
CN111479825A (zh) 2020-07-31
KR20200062215A (ko) 2020-06-03
WO2019063726A1 (en) 2019-04-04
CA3075367A1 (en) 2019-04-04
EP4570826A3 (en) 2025-09-24
US12371484B2 (en) 2025-07-29
US20200407437A1 (en) 2020-12-31
KR102657978B1 (ko) 2024-04-16
EP4570826A2 (en) 2025-06-18
EP3688030B1 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
TWI830761B (zh) 針對cldn18.2和cd3之抗體構建體
JP7818828B2 (ja) 特異的結合分子
JP7456024B2 (ja) Ｉｌ－１７ａ結合ポリペプチド
CN105531370A (zh) 治疗靶向特异性vnar结构域与icosl的分离
CN113660944A (zh) 用于补体相关疾病的融合蛋白构建体
JP2021521781A (ja) 三価三重特異性抗体構築物
JP2021525537A (ja) 三量体ポリペプチド複合体およびその使用
CN110885377B (zh) 抗cd47/vegf双特异性抗体及其应用
CN116829584B (zh) 一种抗pd-1的单域抗体
CN114401987A (zh) 结合剂及其用途
US20250346659A1 (en) Specific binding molecules
WO2023138639A1 (zh) 靶向tigit的抗原结合蛋白及其用途
HK40034041A (en) Il-17a-binding fusion protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230516